BMRN vs. LH: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and LH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | LH |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Labcorp Holdings Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 10.12 billion USD | 21.65 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 26, 1999 | March 29, 1990 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and LH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | LH |
|---|---|---|
| 5-Day Price Return | 0.29% | 3.49% |
| 13-Week Price Return | -7.27% | -2.44% |
| 26-Week Price Return | -11.21% | 6.19% |
| 52-Week Price Return | -21.32% | 9.24% |
| Month-to-Date Return | -1.68% | 2.82% |
| Year-to-Date Return | -19.87% | 13.87% |
| 10-Day Avg. Volume | 3.20M | 1.34M |
| 3-Month Avg. Volume | 2.29M | 0.69M |
| 3-Month Volatility | 25.33% | 24.18% |
| Beta | 0.28 | 1.00 |
Profitability
Return on Equity (TTM)
BMRN
8.84%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.
LH
10.20%
Health Care Providers & Services Industry
- Max
- 24.86%
- Q3
- 15.79%
- Median
- 8.56%
- Q1
- 5.75%
- Min
- -1.64%
LH’s Return on Equity of 10.20% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
BMRN
16.82%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
LH
6.21%
Health Care Providers & Services Industry
- Max
- 11.56%
- Q3
- 5.45%
- Median
- 2.83%
- Q1
- 1.13%
- Min
- -1.71%
A Net Profit Margin of 6.21% places LH in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BMRN
19.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
LH
9.69%
Health Care Providers & Services Industry
- Max
- 19.08%
- Q3
- 9.66%
- Median
- 4.77%
- Q1
- 2.46%
- Min
- -0.83%
An Operating Profit Margin of 9.69% places LH in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BMRN | LH |
|---|---|---|
| Return on Equity (TTM) | 8.84% | 10.20% |
| Return on Assets (TTM) | 7.13% | 4.73% |
| Net Profit Margin (TTM) | 16.82% | 6.21% |
| Operating Profit Margin (TTM) | 19.89% | 9.69% |
| Gross Profit Margin (TTM) | 81.32% | 28.45% |
Financial Strength
Current Ratio (MRQ)
BMRN
4.83
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
LH
1.55
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.51
- Median
- 1.29
- Q1
- 0.92
- Min
- 0.14
LH’s Current Ratio of 1.55 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
LH
0.65
Health Care Providers & Services Industry
- Max
- 2.29
- Q3
- 1.24
- Median
- 0.74
- Q1
- 0.50
- Min
- 0.00
LH’s Debt-to-Equity Ratio of 0.65 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
LH
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.50
- Median
- 4.52
- Q1
- 2.12
- Min
- -4.44
LH’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BMRN | LH |
|---|---|---|
| Current Ratio (MRQ) | 4.83 | 1.55 |
| Quick Ratio (MRQ) | 3.10 | 1.09 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 0.65 |
| Interest Coverage Ratio (TTM) | -21.18 | 5.73 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
LH
1.12%
Health Care Providers & Services Industry
- Max
- 5.93%
- Q3
- 2.59%
- Median
- 1.35%
- Q1
- 0.00%
- Min
- 0.00%
LH’s Dividend Yield of 1.12% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
LH
28.24%
Health Care Providers & Services Industry
- Max
- 185.33%
- Q3
- 74.82%
- Median
- 36.00%
- Q1
- 0.00%
- Min
- 0.00%
LH’s Dividend Payout Ratio of 28.24% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BMRN | LH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.12% |
| Dividend Payout Ratio (TTM) | 0.00% | 28.24% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
19.22
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
BMRN’s P/E Ratio of 19.22 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
LH
25.31
Health Care Providers & Services Industry
- Max
- 40.02
- Q3
- 29.75
- Median
- 21.09
- Q1
- 14.18
- Min
- 7.05
LH’s P/E Ratio of 25.31 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BMRN
3.23
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.23 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
LH
1.57
Health Care Providers & Services Industry
- Max
- 3.15
- Q3
- 1.87
- Median
- 0.74
- Q1
- 0.27
- Min
- 0.09
LH’s P/S Ratio of 1.57 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BMRN
1.72
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
LH
2.74
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.45
- Median
- 2.52
- Q1
- 1.15
- Min
- 0.66
LH’s P/B Ratio of 2.74 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BMRN | LH |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 19.22 | 25.31 |
| Price-to-Sales Ratio (TTM) | 3.23 | 1.57 |
| Price-to-Book Ratio (MRQ) | 1.72 | 2.74 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.11 | 14.55 |